Dermal Drug Selection and Development An Industrial Perspective
The authors show how the pharmaceutical industry faces the development of dermal drugs and provide the only book of its kind that describes how the industry develops and selects dermal drugs, complete with the challenges and opportunities of the field. De
- PDF / 5,203,064 Bytes
- 154 Pages / 439.42 x 683.15 pts Page_size
- 88 Downloads / 227 Views
rmal Drug Selection and Development An Industrial Perspective
Dermal Drug Selection and Development
Lionel Trottet • Howard Maibach
Dermal Drug Selection and Development An Industrial Perspective
Lionel Trottet Oncodesign Centre de Recherches François Hyafil Villebon sur Yvette, France [email protected]
Howard Maibach, MD Dermatology Department Medical School University of California San Francisco, CA, USA [email protected]
ISBN 978-3-319-59503-0 ISBN 978-3-319-59504-7 (eBook) DOI 10.1007/978-3-319-59504-7 Library of Congress Control Number: 2017943165 © Springer International Publishing AG 2017 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Printed on acid-free paper This Springer imprint is published by Springer Nature The registered company is Springer International Publishing AG The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland
To Elena, Silvia, Claudia and Luca
Preface
Delivery of drugs through skin has been an attractive area for research and for pharmaceutical companies as it can offer larger therapeutic window compared to systemic delivery. Dermal drug development started back in the 1950s with corticosteroids as, despite impressive efficacy, corticosteroids use was limited because of the serious adverse events observed when administered systemically for long periods. The efficacy of topically delivered hydrocortisone then paved the way to further corticosteroid drug developments. Over the years the successful development of retinoids, vitamin D3 derivatives and immuno-suppressors has further proved the dermal potential for drug target classes with difficult safety profile. In the last 15 years, the strong move of the pharmaceutical industry to focus on new mechanisms of action—rather than “me too” approaches—has multiplied the number of new target classes that could address skin diseases. Moreo
Data Loading...
